In the rat brain, destruction of dopaminergic cell groups by injections of 6-hydroxydopamine into the ventral mesencephalic tegmentum results in large decreases in the number of neurotensin binding sites in the mesencephalon and the striatum. In contrast, these lesions produce an increase in the number of 1251-labeled neurotensin binding sites in the lateral part of the prefrontal cortex despite a large decrease in cortical dopamine levels. Increases; in the number of 125I-labeled neurotensin binding sites in this cortical area as well as in the entorhinal cortex, the nucleus accumbens, and the central part of the striatum were also obtained after chronic blockade of dopamine neurotransmission by a long-acting neuroleptic pipotiazine palmitic ester. We propose that dopamine inputs regulate the density of postsynaptic neurotensin binding sites through cortical and subcortical dopamine receptors. Therefore, some of the clinical effects of neuroleptics in schizophrenic patients could be partly related to changes in neurotensin neurotransmission.
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Neurotensin (NT) is a tridecapeptide that is unevenly distributed in mammalian brain (1) (2) (3) (4) . High levels of NT immunoreactivity have been found in some structures innervated by ascending dopaminergic neurons, such as the nucleus accumbens or the striatum, while relatively little NT immunoreactivity was detected in others, such as the prefrontal cortex (5, 6) . Histochemical studies have also revealed the occurrence of NT immunoreactive fibers in the ventral mesencephalic tegmentum (VMT) and in the zona compacta and pars lateralis of the substantia nigra (SN) surrounding dopamine-containing cell bodies and their dendrites (7) . In addition, numerous neuronal perikarya of the VMT contain NT immunoreactivity: NT and dopamine coexist in some VMT neurons (7) and the existence of a VMT NT projection to the median nucleus accumbens has been also described (8) .
There is some indication that NT stimulates the firing rate of nigral dopaminergic cells (9) , and several biochemical and behavioral studies have suggested that intraventricularly or locally injected NT can activate dopaminergic cells located either in the VMT or in the SN (10) (11) (12) (13) (14) . For example, in the rat, the injection of NT into the VMT produced concomitant increases in the levels of dihydroxyphenylacetic acid in the nucleus accumbens and in locomotor activity (13) . Moreover, one of the most striking features of the autoradiographic distribution of [3H]NT binding sites was its similarity to the topographic localization of dopaminergic cell bodies in the ventral mesencephalon (15, 16) . Lesion studies have confirmed the presence of [3H]NT binding sites on mesencephalic dopaminergic neurons. Injection of 6-hydroxydopamine into the VMT and the SN led to the destruction of the ascending dopaminergic neurons and was associated with a marked decrease in [3H]NT binding in the mesencephalon (17, 18) . In addition, a reduction of [3H]NT binding was observed in dopaminergic terminal areas such as the striatum and the olfactory tubercles (17) .
Although interactions between NT and dopaminergic neurons are well-documented, there is no report about the influence of dopamine neurotransmission on the NT binding sites located post-synaptically to the dopaminergic neurons. In the present study, two approaches were used to chronically interrupt dopamine transmission: the first consisted of the destruction of ascending dopaminergic neurons by bilateral injections of 6-hydroxydopamine into the VMT, and the second took advantage of the property of a long-acting neuroleptic, the pipotiazine palmitic ester, to chronically block dopamine receptors. Changes in NT binding sites were examined by using in vitro quantitative autoradiography of '25I-labeled [Tyr3] NT (1251-NT) binding (19, 20 
METHODS
Animals and Surgery. Sprague-Dawley rats (250-300 g) (Charles River, Elbeuf, France) were used. They were kept in stable conditions oftemperature (22°C) and humidity (65%) in a 12-hr light/dark cycle. Rats were anesthetized with ketamine (130 mg/kg) and were fixed on a Kopf stereotaxic apparatus with incisor bars placed 3.4 mm above the interaural line. Dopaminergic cell bodies were lesioned by bilateral microinjections of 1 ,ul of a solution containing 6-hydroxydopamine (4 mg/ml), NaCl (9 mg/ml), and ascorbic acid (0.2 mg/ml) adjusted to pH 4.5. Microinjection cannulae were placed stereotaxically 4.3 mm posterior to and ± 0.5 mm lateral to the Bregma and 8.7 mm under the surface of the skull. The 6-hydroxydopamine solution was delivered slowly by a Hamilton syringe attached to a Braun-Melsungen pump (1 ,u per 3 min).
Long-Acting Neuroleptic Treatment. The long-acting neuroleptic, pipotiazine palmitic ester, which has already been used successfully to analyze the effects of long-term impregnation with neuroleptics on dopamine transmission (21) , was injected subcutaneously 40, 20, and 5 days before sacrifice (Piportil L4; 32 mg/kg, expressed as weight of pipotiazine). The efficiency of the neuroleptic treatment was tested by measuring the locomotor activity of the animals according to the method of LeMoal et al. (22) . All the treated animals used Abbreviations: NT, neurotensin; 125I-NT, 125I-labeled [Tyr3]NT; SN, substantia nigra; VMT, ventral mesencephalic tegmentum.
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in the present study exhibited a locomotor activity < 40% of that of controls.
Estimation of Dopamine Levels. The efficiency of the 6-hydroxydopamine lesions was tested by measuring dopamine levels according to the following procedure: animals were stunned by a blow to the thorax and sacrificed by decapitation. Microdiscs of tissue from the ventral tegmental area, medial and lateral SN, prefrontal cortex, nucleus accumbens, and central and lateral striatum were dissected out of frozen sections 500 ,m thick using 0.9-mm or 1.4-mm (prefrontal cortex) diameter cylindrical tubes. Tissue samples were immersed in 110 ,ul of a 0.1 M perchloric acid/0.01 M thioglycollic acid solution, sonicated, and centrifuged for 20 min at 20,000 x g. Catechols were isolated from supernatants on alumina microcolumns and dopamine levels were estimated by a radioenzymatic method derived from Gauchy et al. (23) . In all structures examined, 6-hydroxydopamine injections into the VMT decreased dopamine levels by > 85% except in the prefrontal cortex (80% decrease) and the lateral striatum (74% decrease).
In Vitro Autoradiography of '2MI-NT Binding Sites. 6-Hydroxydopamine lesioned neuroleptic-treated, and control rats were sacrificed by decapitation and their brains were frozen rapidly on dry ice. Sections (20 Am thick) were cut with a cryostat at different levels, determined by using the atlas of Paxinos and Watson (24), to include the prefrontal cortex, the anterior nucleus accumbens, the central striatum, and the mesencephalic dopaminergic cell bodies. Sections were mounted onto gelatin-coated glass slides and stored at -80'C until the day of the experiment. For each level, [8] [9] [10] sections were incubated for 60 min at 40C in a solution containing 0.1 nM 1251I-NT (2000 Ci/mmol; 1 Ci = 37 GBq), 50 mM Tris HCl buffer (pH 7.5), 5 mM MgCl2, 0.2% bovine serum albumin, and 20 ,M bacitracin (19, 20) . Nonspecific binding was determined in parallel incubations, which included 500 nM unlabeled NT (20) .
Sections were washed four times for 2 min each in ice-cold 50 mM TrisHCl buffer, dipped in distilled water, and dried under a stream of cold air. Finally, they were opposed to 3H Ultrofilm (LKB, Orsay, France) for 3 weeks at room temperature in the dark. Autoradiograms were analyzed quantitatively with 125I standards using a densitometer (25, 26) . Data are expressed as means ± SEM in fmol per mg of protein. Competition curves were obtained by incubating brain sections at the same anatomical levels with 0.1 nM 125I-NT in the presence of increasing concentrations of unlabeled NT. In each brain structure, optical densities for various concentrations of unlabeled NT were directly measured on the film autoradiographs (25, 27) . Values were obtained by averaging six readings of different sections and converted into fmol per mg of protein (26) . RESULTS Effects of VMT 6-Hydroxydopamine Lesions on 125I-NT Binding. Six weeks following 6-hydroxydopamine lesions in the VMT, very large decreases in 125I-NT binding were observed and quantified at the level of dopaminergic cell bodies ( Fig. 1) .
In forebrain areas innervated by dopaminergic neurons, the 6-hydroxydopamine lesions induced various effects on 125I-NT binding (Fig. 2) : although 125I-NT binding was reduced in the central and lateral parts of the striatum, no significant modification was observed in the median part of the prefrontal cortex, the entorhinal cortex, and the nucleus accumbens. Surprisingly, a significant increase in the density of 1251-NT binding occurred in the lateral part ofthe prefrontal cortex just above the forceps minor (Fig. 3) , an area known to be innervated by dopaminergic fibers (28, 29) .
Since slices were incubated with a single concentration of '25I-NT (0.1 nM) much lower than the Kd value (5 nM; ref. 20), competition curves were also constructed to investigate whether the modifications in binding observed in various dopaminergic areas were due to a change in the number and/or in the affinity of the binding sites (Fig. 4) . The results obtained were in good agreement with those reported in Figs. 1 and 2, with 125I-NT binding in lesioned animals being increased in the lateral prefrontal cortex, unaffected in the nucleus accumbens, and decreased in the lateral striatum and the ventral tegmental area. In addition, comparison of the concentrations of NT required to decrease 125I-NT binding by 50% in the lateral part of the prefrontal cortex revealed that there was no important difference in the apparent affinity of NT binding sites between control and lesioned rats (Fig. 4) , suggesting that the increase of 125I-NT binding is due to a change in the number of 125I-NT binding sites.
A high density of 125I-NT binding sites was also seen in several structures devoid of dopaminergic nerve terminals or cell bodies. Although a complete quantitative analysis of the effect of the 6-hydroxydopamine lesions was not made in all these brain structures, no modification in 125I-NT binding could be detected in those examined (Table 1) .
Effects of Pipotiazine Palmitate Treatment on '25I-NT Binding. The increase in 125I-NT binding observed in the lateral part of the prefrontal cortex following destruction of the ascending dopaminergic fibers suggested that the blockade of dopamine transmission was responsible for the increase in the number of NT binding sites. To test this hypothesis further, DA transmission was blocked chronically by a long-acting neuroleptic, the pipotiazine palmitic ester.
Six weeks after the onset of the neuroleptic treatment (three injections), either no change or a small reduction in 125I-NT binding occurred in the VMT and the SN (Fig. 1) rupt dopamine transmission, but 6-hydroxydopamine lesions destroy NT binding sites located on dopaminergic neuronal cell bodies and fibers (presynaptic NT binding sites) while neuroleptic treatment preserves them. As a consequence, if postsynaptic NT binding sites are regulated by dopaminergic innervation, it is expected that 6-hydroxydopamine lesions will modify the density of both pre-and postsynaptic NT binding sites, while neuroleptic treatment will change only postsynaptic NT binding sites. For instance, our data in the SN and VMT show a marked decrease in 125I-NT binding in 6-hydroxydopamine lesioned animals and, in contrast, no change or a slight decrease in neuroleptic-treated animals. This indicates that a large proportion of NT binding sites are located on dopaminergic perikarya and dendrites in the SN and VMT, thus confirming the results of others (17, 18) . This is also in good agreement with the finding that the degeneration of cell bodies in Parkinson disease is associated with an almost total disappearance of NT binding sites in the SN (30, 31) . However, the lack of effect of neuroleptic treatment on 125I-NT binding in the SN is at variance with recent results of Uhl and Kuhar (32) who reported that [3H]NT binding was enhanced in the SN of rats and humans after repeated treatment with neuroleptics. No explanation can yet be provided for this discrepancy, but our results clearly show that pipotiazine palmitate treatment does not increase the number of NT binding sites located on dopaminergic neurons.
At the level of subcortical dopaminergic terminal fields, various situations arise. Similar to the SN and VMT, the lateral striatum shows a large decrease in 125I-NT binding following 6-hydroxydopamine lesions and no change after neuroleptic treatment. These results indicate, in agreement with others (17) , that NT binding sites are not only located on dopaminergic perikarya and dendrites but also on dopaminergic nerve terminals in the nigrostriatal dopamine pathway. The existence of a large proportion ofpresynaptic NT binding sites in the striatum agrees well with biochemical evidence that NT exerts a presynaptic control on the release of striatal dopamine (33, 34) . In the nucleus accumbens, unlike in the striatum, a 6-hydroxydopamine lesion does not affect 125I-NT binding, whereas neuroleptic treatment increases 125I-NT binding. It therefore appears that a substantial population of NT binding sites are located postsynaptically to dopaminergic nerve terminals in the nucleus accumbens and that these sites are up-regulated when dopamine transmission is interrupted. The apparent lack of reduction of NT binding in the nucleus accumbens of6-hydroxydopamine lesioned rats, also noted by others (17) , may be interpreted as resulting from the conjunction of a loss ofpresynaptic NT binding sites together with the appearance of new postsynaptic NT binding sites. The existence of both pre-and postsynaptic NT binding sites in the nucleus accumbens is compatible with behavioral and biochemical data showing that, in this brain area, NT affects dopamine transmission at pre-and postsynaptic levels (13, 
35, §).
Of great interest are the data obtained at the level of cortical dopaminergic terminal fields. The distribution of NT binding sites in these brain areas following 6-hydroxydopamine lesion or neuroleptic treatment has not been previously studied. It is striking that '25I-NT binding is increased in the prefrontal and the entorhinal cortices following neuroleptic treatment. Furthermore, in 6-hydroxydopamine lesioned animals, NT binding is markedly increased in the lateral prefrontal cortex and slightly, although not significantly, increased in the median prefrontal cortex and in the entorhinal cortex. Our data favor the possibility that, in the §Coquerel, A., Dubuc, I., Menard, J. (42, 43) . In addition, in a postmortem study, increased NT levels were observed in the prefrontal cortex (Brodman's area 32) of schizophrenic patients (44) . These observations, as well as the heteroregulation of the density of corticolimbic I251-NT binding sites by dopaminergic afferents described in the present study could suggest that some of the clinical effects of neuroleptics seen in schizophrenic patients are partly mediated by changes in NT neurotransmission.
